Safety of Insulin Degludec/Insulin Aspart in Patients with Diabetes Mellitus over a Period of 1 Year during Routine Clinical Care in India: SMART (Study of Management of Diabetes with Ryzodeg™ Treatment)

This post-authorization study was conducted to evaluate the safety of insulin degludec/insulin aspart (IDegAsp) in adult patients with diabetes mellitus (DM) during routine clinical care under a real-world setting in India. Eligible patients received IDegAsp for a minimum of 12 months during routine...

Descripción completa

Detalles Bibliográficos
Autores principales: Kesavadev, Jothydev, Gowda, Ambanna, Kumar, Harish, Yalamanchi, Sadasiva Rao, Lodha, Sailesh, Singh, Kiran Pal, Basu, Debasis, Asirvatham, Arthur, Shah, Navneet, Pathan, Muzammil Khan, Revanna, Manjunatha, Mukherjee, Jagat Jyoti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788540/
https://www.ncbi.nlm.nih.gov/pubmed/35076540
http://dx.doi.org/10.3390/medsci10010001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788540/
https://www.ncbi.nlm.nih.gov/pubmed/35076540
http://dx.doi.org/10.3390/medsci10010001

Ejemplares similares